Professor Jaime King’s article, “The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs,” coauthored with Katherine Gudiksen and published in Journal of Legal Medicine, is a clear and cogent piece that adds to her distinguished scholarship on some of the most complex challenges facing the U.S. healthcare system. In the process,… Continue reading →
When Governor Jerry Brown signed California’s drug transparency law, Senate Bill 17 (SB-17), in 2017, the state took a crucial first step towards increased transparency and accountability in a landscape of skyrocketing prescription-drug prices. Not only does SB-17 require drug manufacturers and health insurers to disclose information about rising prescription-drug prices, but it also represents… Continue reading →
What drives health care costs ever higher? Consolidation may be playing a key role. In this context, Professor Jaime King’s contribution to the St. Louis University Annual Health Law Symposium, “The Anti-Competitive Potential of Cross-Market Mergers in Health Care” (coauthored with Erin C. Fuse Brown), is a clarion call for antitrust authorities to consider seriously… Continue reading →
